How do clinicians monitor patients on chronic opioid therapy for safety and efficacy?

• A. Urine drug screening is never used
• B. Regular pain and function assessments; adverse effect monitoring; risk assessment for misuse; urine drug screening where indicated; prescription monitoring; adherence checks; periodic therapy reevaluation
• C. Frequent imaging every week
• D. Discontinue opioids at the first sign of any adverse effect

Answer: (B)

Monitoring chronic opioid therapy involves a structured, ongoing approach to balance benefit and risk. Clinicians should regularly assess both pain relief and function to determine if the therapy is helping the patient achieve meaningful improvement in daily activities. They must also vigilantly monitor for adverse effects and safety concerns, such as constipation, sedation, respiratory depression, and potential endocrine or immune effects, adjusting the plan as needed.

Assessing risk for misuse or problematic use is essential, with attention to behaviors that may indicate diversion or nonmedical use. Urine drug screening is used when indicated to confirm that the patient is taking prescribed opioids and not using non-prescribed substances. Prescription monitoring programs help track opioid access across providers and pharmacies, reducing the chance of unsafe patterns like doctor shopping or dangerous drug combinations. Adherence checks, such as reviewing pharmacy refill history or performing pill counts, support accurate dosing and risk management.

Periodic reevaluation of the therapy ensures the benefits continue to outweigh risks, guiding decisions about continuing, adjusting the dose, adding nonopioid or nonpharmacologic strategies, or tapering and discontinuing if appropriate. Imaging on a weekly basis is not part of routine monitoring, and stopping opioids at the first adverse effect without evaluation is not appropriate; adverse effects are managed and the plan is adjusted rather than abruptly halted.